Research graph
References from Eplerenone Revisited: A Balanced Reappraisal of Its Role in Hypertension, Heart Failure, and Cardiorenal Disease. Local targets link to admitted publications; unresolved targets remain external evidence.
The effect of spironolactone on morbidity and mortality in patients with severe heart failure
10.1056/nejm199909023411001 · 1999 · External reference
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction
10.1056/nejmoa030207 · 2003 · External reference
Eplerenone in patients with systolic heart failure and mild symptoms
10.1056/nejmoa1009492 · 2011 · External reference
Eplerenone: an underused medication?
10.1177/1074248410371946 · 2010 · External reference
Antihypertensive effect of the mineralocorticoid receptor antagonist eplerenone: a pooled analysis of patient-level data from comparative trials using regulatory-approved doses
10.2147/vhrm.s170141 · 2018 · External reference
Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study
10.1161/01.cir.0000091405.00772.6e · 2003 · External reference
Albuminuria-lowering effect of dapagliflozin, eplerenone, and their combination in patients with CKD: a randomized crossover clinical trial
10.1681/asn.2022020207 · 2022 · External reference
Efficacy and safety of eplerenone for treating chronic kidney disease: a meta-analysis
10.1155/2023/6683987 · 2023 · External reference
Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes
10.1056/nejmoa2025845 · 2020 · External reference
Cardiovascular events with finerenone in kidney disease and type 2 diabetes
10.1056/nejmoa2110956 · 2021 · External reference
Association between mineralocorticoid receptor antagonists and kidney harm: a systematic review and meta-analysis of randomized controlled trials
10.1002/phar.4618 · 2025 · External reference
Adverse events associated with early initiation of eplerenone in patients hospitalized for acute heart failure
10.1016/j.ijcard.2024.132477 · 2024 · External reference
Unmasking hormonal mechanisms of hypertension in obesity
10.1016/j.jacbts.2026.101526 · 2026 · External reference
2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM guideline for the prevention, detection, evaluation and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines
10.1161/hyp.0000000000000257 · 2025 · External reference
Aldosterone induces a vascular inflammatory phenotype in the rat heart
10.1152/ajpheart.01096.2001 · 2002 · External reference
Aldosterone and vascular inflammation
10.1161/hypertensionaha.107.095489 · 2008 · External reference
Aldosterone and mineralocorticoid receptor signaling as determinants of cardiovascular and renal injury: from Hans Selye to the present
10.1159/000515622 · 2021 · External reference
Mineralocorticoid receptors and cardiovascular damage: it's not just aldosterone
10.1161/01.hyp.0000203732.03784.3b · 2006 · External reference
Mineralocorticoid receptors in the pathophysiology of chronic kidney diseases and the metabolic syndrome
10.1016/j.mce.2011.07.018 · 2012 · External reference
The unrecognized prevalence of primary aldosteronism: a cross-sectional study
10.7326/m20-0065 · 2020 · External reference
Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis
10.1016/s2213-8587(17)30319-4 · 2018 · External reference
The expanding spectrum of primary aldosteronism: implications for diagnosis, pathogenesis, and treatment
10.1210/er.2018-00139 · 2018 · External reference
The effects of eplerenone on the circadian blood pressure pattern and left ventricular hypertrophy in patients with obstructive sleep apnea and resistant hypertension-A randomized, controlled trial
10.3390/jcm8101671 · 2019 · External reference
Renin phenotypes characterize vascular disease, autonomous aldosteronism, and mineralocorticoid receptor activity
10.1210/jc.2016-3867 · 2017 · External reference
Mineralocorticoid receptor antagonists: the evolution of utility and pharmacology
10.1046/j.1523-1755.2000.00983.x · 2000 · External reference
Comparative effectiveness and safety of eplerenone and spironolactone in patients with heart failure: a systematic review and meta-analysis
10.1186/s12872-024-04103-7 · 2024 · External reference
Effects of the selective aldosterone blocker eplerenone versus losartan in patients with essential hypertension
10.1161/01.hyp.0000067463.13172.ea · 2003 · External reference
Effects of eplerenone versus enalapril in essential hypertension
2002 · External reference
Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients
10.1161/01.hyp.0000025146.19104.fe · 2002 · External reference
Incidence and prognosis of resistant hypertension in hypertensive patients
10.1161/circulationaha.111.068064 · 2012 · External reference
Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial
10.1016/s0140-6736(15)00257-3 · 2015 · External reference
Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study
10.1056/nejm199005313222203 · 1990 · External reference
Prognostic significance of serial changes in left ventricular mass in essential hypertension
10.1161/01.cir.97.1.48 · 1998 · External reference
Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism
10.1006/jmcc.1993.1066 · 1993 · External reference
Aldosterone induces acute endothelial dysfunction in vivo in humans: evidence for an aldosterone-induced vasculopathy
10.1042/cs1030425 · 2002 · External reference
Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats
10.1161/01.hyp.31.1.451 · 1998 · External reference
Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients
10.1161/hypertensionaha.107.103267 · 2008 · External reference
Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure
10.1016/j.jacc.2005.04.038 · 2005 · External reference
Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction
10.1161/01.cir.0000068340.96506.0f · 2003 · External reference
2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure
10.1093/eurheartj/ehab368 · 2021 · External reference
2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines
2022 · External reference
Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry
10.1016/j.jacc.2018.04.070 · 2018 · External reference
Spironolactone for heart failure with preserved ejection fraction
10.1056/nejmoa1313731 · 2014 · External reference
Regional variation in patients and outcomes in the treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial
10.1161/circulationaha.114.013255 · 2015 · External reference
Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy
10.1161/01.cir.0000139860.33974.28 · 2004 · External reference
Albuminuria is an appropriate therapeutic target in patients with CKD: the pro view
10.2215/cjn.11511114 · 2015 · External reference
Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes
10.2215/cjn.00240106 · 2006 · External reference
True rate of mineralocorticoid receptor antagonists-related hyperkalemia in placebo-controlled trials: a meta-analysis
10.1016/j.ahj.2017.03.011 · 2017 · External reference
Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis
10.1093/eurheartj/ehab777 · 2022 · External reference
Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease
10.1093/eurheartj/ehac299 · 2022 · External reference
A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease
10.1093/eurheartj/ehw132 · 2016 · External reference
Adherence in hypertension
10.1161/circresaha.118.313220 · 2019 · External reference
Single-pill combination therapy for the management of hypertension: a scientific statement from the American heart Association
10.1161/hyp.0000000000000258 · 2026 · External reference
Effectiveness of fixed-dose combination medication (“polypills”) compared with usual care in patients with cardiovascular risk: a systematic review and meta-analysis
2016 · External reference
Meta-analysis of dose-response characteristics of hydrochlorothiazide and chlorthalidone
2010 · External reference
Major outcomes in high-risk hypertensive patients randomized to ACE inhibitor or calcium channel blocker vs diuretic
10.1001/jama.288.23.2981 · 2002 · External reference
